Citations

Showing 10 of 108094 citations.

Direct Cervical Carotid Stenting and Angioplasty of Right Internal Carotid Artery and Brachiocephalic Artery Ostial Stenoses With Flow Reversal: 2-Dimensional Operative Video
Rangel-Castilla, Leonardo , Siddiqui, Adnan H. , Siddiqui, Adnan H , Levy, Elad I.

Mayo Clinic

Operative Neurosurgery | May 28, 2018 | Volume: 16 | Issue: 2 | Pages: 269-270

10.1093/ons/opy113 | PMID 29846684 Get It

Abstract We present a case of tandem stenosis of the great vessels (cervical internal carotid artery [ICA] and brachiocephalic trunk ostium [BTO]) treated with stenting and balloon angioplasty of both lesions under flow arrest. A 70-yr-old woman with a history of hypertension, hyperlipidemia, coronary artery disease, and previous strokes presented with recurrent transient ischemic attacks of the left upper and lower extremities over the last 6 mo. She underwent right cervical endarterectomy (CEA) 16 yr prior. Neurological examination was unremarkable. Carotid Doppler ultrasonography revealed severely increased velocities of the right ICA. Cervical magnetic resonance angiography demonstrated 80% right ICA stenosis and 50% BTO stenosis. Digital subtraction cerebral angiography showed 80% right ICA stenosis and 70% BTO stenosis. The patient was not a candidate for standard carotid artery stenting because the BTO precluded endovascular access or for CEA because of the previous CEA; therefore, direct carotid access and flow reversal was an alternative. Under general anesthesia and systemic heparinization, the patient underwent right carotid artery surgical exposure. Under flow reversal using the Enroute System (Silk Road Medical, Sunnyvale, California), anterograde right ICA stenting angioplasty and retrograde BTO stenting and angioplasty were performed. Successful revascularization of the right ICA and BTO was obtained. No procedure-related complications occurred. The patient was discharged home 2 d postprocedure, neurologically intact. Direct carotid access with flow reversal is a safe and effective therapeutic alternative for patients with ICA (or common carotid artery) stenosis who cannot undergo CEA or when endovascular access from the aortic arch is not possible. Patient consent was obtained prior to performing the procedure. Institutional board approval is not required for the report of a single case.
A Retrospective Study Analyzing the Appropriateness of Initial Treatment of Clostridium difficile in Patients with Active Malignancy
Fisher, Aaron , Khanal, Pradeep, Gniado, Ewa, Khaddour, Leila, Orosey, Molly , Hader, Ismail , Yadav, Siddhartha , Halalau, Alexandra , Yadav, Siddhartha , Halalau, Alexandra

Mayo Clinic

Gastroenterology Research and Practice | May 27, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/7192728 | PMID 29991944 Get It

Background. Clostridium difficile infection (CDI) is the leading cause of hospital-associated gastrointestinal illness. Previous studies reported that patients with active malignancy are at high risk for CDIs, and yet they are still classified as nonsevere CDI and initially treated with metronidazole. Our aim is to investigate the need for the escalation of antibiotic therapy in patients with CDI and active cancer treated with oral metronidazole versus oral vancomycin. Methods. This is a retrospective study of adult patients admitted with CDI and any underlying active malignancy at Beaumont Hospital, Royal Oak, Michigan, from January 2008 to December 2014. Inclusion criteria included age > 18 years old, polymerase chain reaction- (PCR-) proven CDI, and active malignancy. Results. 197 patients were included in the final analysis. 44.8% of the metronidazole group required escalation of therapy compared to 15.2% in the vancomycin group (p value = 0.001). 29.8% of the combination group (metronidazole and vancomycin) underwent deescalation of antibiotics, which was significantly higher compared to 2.2% of patients in the vancomycin group (p value < 0.001). Discussion. Our results support the initial use of vancomycin or a combination (metronidazole and vancomycin) versus metronidazole in patients with CDI and active malignancy.
Cardiac diseases among liver transplant candidates
Gitman, Marina , Albertz, Megan , Nicolau‐Raducu, Ramona , Aniskevich, Stephen , Pai, Sher‐Lu , Pai, Sher-Lu , Aniskevich, Stephen

Mayo Clinic

Clinical Transplantation | May 27, 2018 | Volume: 32 | Issue: 7 | Pages: No page available

10.1111/ctr.13296 | PMID 29804298 Get It

AbstractImprovements in early survival after liver transplant (LT) have allowed for the selection of LT candidates with multiple comorbidities. Cardiovascular disease is a major contributor to post‐LT complications. We performed a literature search to identify the causes of cardiac disease in the LT population and to describe techniques for diagnosis and perioperative management. As no definite guidelines for preoperative assessment (except for pulmonary heart disease) are currently available, we recommend an algorithm for preoperative cardiac work‐up.
CORR Insights®: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases
Kremers, Hilal Maradit , Maradit Kremers, Hilal, Maradit Kremers, Hilal

Mayo Clinic

Clinical Orthopaedics & Related Research | May 26, 2018 | Volume: 476 | Issue: 7 | Pages: 1452-1454

10.1097/corr.0000000000000355 | PMID 29846204 Get It

Impact of bowel management in alleviating symptoms of urinary incontinence in patients with spina bifida associated with overactive bladder and detrusor sphincter dyssynergia
Radojicic, Zoran , Milivojević, Saša , Milić, Nataša , Milin‐Lazović, Jelena , Lukač, Marija , Sretenović, Aleksandar , Milic, N

Mayo Clinic

BJU International | May 26, 2018 | Volume: 123 | Issue: 1 | Pages: 118-123

10.1111/bju.14414 | PMID 29802783 Get It

Objective To examine the effects of bowel management on urinary incontinence in patients with spina bifida associated with overactive bladder ( OAB ) and detrusor sphincter dyssynergia ( DSD ). Materials and Methods The research was carried out during the period 2014–2017. A total of 35 patients (group 1) were administered bowel management combined with anticholinergic medication therapy and clean intermittent catheterization ( CIC ) and 35 patients (group 2) were treated only with anticholinergic medication therapy and CIC . Bowel management included daily enema, laxative application and a special diet, with the aim of treating constipation, evaluated according to the Roma III criteria and echosonographically determined transversal rectal diameter. The effects of the administered bowel management on urinary incontinence were assessed according to the mean dry interval between two CIC s for all patients. All patients were followed up for 1 year, during which data were prospectively collected. Results There was no statistically significant difference with regard to age, gender and baseline clinical features between the two groups. In group 1, the mean ± sd dry interval between two CIC s was 150.0 ± 36.4 min, and group 2 it was 101.3 ± 51.6 min. There was a significant difference in urinary incontinence, i.e. in the mean dry interval, between the two groups ( P < 0.001). Conclusion Administering bowel management considerably increased the mean dry interval, thus greatly alleviating the symptoms of urinary incontinence. For this reason, bowel management should form an integral part of the treatment of patients with spina bifida and OAB and DSD .
New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia
Khachaturian, Ara S. , Hayden, Kathleen M. , Mielke, Michelle M. , Lutz, Michael W. , Gold, Michael , Kukull, Walter A. , Mohs, Richard C. , Gauthier, Serge , Khachaturian, Zaven S., Mielke, Michelle M , Tang, Yi , Molinuevo, José Luís , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | May 26, 2018 | Volume: 14 | Issue: 6 | Pages: 703-706

10.1016/j.jalz.2018.05.002 | PMID 29842864 Get It

Update on the role of lenalidomide in patients with multiple myeloma
Holstein, Sarah A. , Suman, Vera J. , McCarthy, Philip L.

Mayo Clinic

Therapeutic Advances in Hematology | May 26, 2018 | Volume: 9 | Issue: 7 | Pages: 175-190

10.1177/2040620718775629 | PMID 30013765 Get It

Lenalidomide is a derivative of thalidomide and belongs to the class of drugs known as the immunomodulatory drugs (IMiDs). The IMiDs have played a large role in improving the survival outcomes of patients with multiple myeloma. In particular, lenalidomide is currently standard of care in the newly diagnosed setting, in the maintenance setting post-autologous stem cell transplant, as well as in the relapsed/refractory setting. While the combination of lenalidomide and various proteasome inhibitors has proven particularly effective, there are emerging data demonstrating the effectiveness of lenalidomide in combination with other important classes of drugs including the monoclonal antibodies. Recent studies have provided insight into the molecular target of lenalidomide and the other IMiDs, although there is still much to be learned regarding the mechanisms by which lenalidomide affects the myeloma cell and the immune system. Here we review the molecular mechanisms of action, side effects, and the results of the clinical trials which have led to the widespread incorporation of lenalidomide into the myeloma therapeutic armamentarium.
Outcomes of repeat balloon assisted enteroscopy in small-bowel bleeding
Al‐Bawardy, Badr , Ramos, Guilherme Piovezani , Lennon, Ryan J. , Gorospe, Emmanuel C., Song, Louis M. Wong Kee , Bruining, David H. , Alexander, Jeffrey A. , Fidler, Jeff L. , Rajan, Elizabeth , Piovezani Ramos, Guilherme, Gorospe, Emmanuel, Wong Kee Song, Louis M, Ramos, Guilherme P , Coelho–Prabhu, Nayantara , Fidler, Jeff L.

Mayo Clinic

Endoscopy International Open | May 25, 2018 | Volume: 06 | Issue: 06 | Pages: E694-E699

10.1055/a-0599-6085 | PMID 29868634 Get It

Abstract Background/aims The rate of recurrent small-bowel bleeding (SBB) remains high despite the advent of balloon assisted enteroscopy (BAE). The study aims were to determine: (1) the diagnostic and therapeutic yields, and adverse event rate of repeat BAE in SBB, and (2) the predictors of a positive repeat BAE. Methods A retrospective review of a BAE database was conducted. Patients who had > 1 BAE for SBB were included. Primary outcomes were diagnostic yield, therapeutic yield, and adverse events of repeat BAE. Secondary outcomes were predictors of a positive repeat BAE. Results A total of 175 patients (55 % men; mean age 64.1 ± 16.3 years) were included. The diagnostic and therapeutic yields of repeat BAE were 55 % and 42 %, respectively. Repeat BAE adverse events occurred in 5 % with self-limited abdominal pain being most common. Patients with a positive repeat BAE were significantly older than the negative group (68.6 ± 13.9 vs. 60.9 ± 17.1; P = 0.001) and were more likely to have cardiac comorbidities (OR 2.4, 95 %CI: 1.3 – 4.6; P = 0.01), chronic kidney disease (OR 2.3, 95 %CI: 1.1 – 4.9; P = 0.04), chronic obstructive pulmonary disease (OR 3.3, 95 %CI: 1.3 – 8.1; P = 0.01), positive initial BAE (OR 3.6, 95 %CI: 1.9 – 6.8; P < 0.001), and antegrade procedure (OR 3.3, 95 %CI: 1.7 – 6.1; P < 0.001). On multivariate analysis, a positive initial BAE and antegrade route were the only significant predictive factors. Conclusions Performing a repeat BAE for SBB appears safe and provided modest yields. A positive initial BAE and antegrade route were predictive of a positive repeat BAE.
Human interleukin‐10 delivered intrathecally by self‐complementary adeno‐associated virus 8 induces xenogeneic transgene immunity without clinical neurotoxicity in swine
Unger, Mark, Pleticha, Josef, Heilmann, L. , Newman, Laura K. , Maus, Timothy P. , Beutler, Andreas S. , Unger, Mark D, Heilmann, Lukas F

Mayo Clinic

The Journal of Gene Medicine | May 25, 2018 | Volume: 20 | Issue: 7-8 | Pages: No page available

10.1002/jgm.3026 | PMID 29800509 Get It

AbstractIntroductionIntrathecal interleukin (IL)‐10 delivered by plasmid or viral gene vectors has been proposed for clinical testing because it is effective for chronic pain in rodents, is a potential therapeutic for various human diseases, and was found to be nontoxic in dogs, when the human IL‐10 ortholog was tested. However, recent studies in swine testing porcine IL‐10 demonstrated fatal neurotoxicity. The present study aimed to deliver vector‐encoded human IL‐10 in swine, measure expression of the transgene in cerebrospinal fluid and monitor animals for signs of neurotoxicity.ResultsHuman IL‐10 levels peaked 2 weeks after vector administration followed by a rapid decline that occurred concomitant with the emergence of anti‐human IL‐10 antibodies in the cerebrospinal fluid and serum. Animals remained neurologically healthy throughout the study period.ConclusionsThe findings of the present study suggest that swine are not idiosyncratically sensitive to intrathecal IL‐10 because, recapitulating previous reports in dogs, they suffered no clinical neurotoxicity from the human ortholog. These results strongly infer that toxicity of intrathecal IL‐10 in large animal models was previously overlooked because of a species mismatch between transgene and host. The present study further suggests that swine were protected from interleukin‐10 by a humoral immune response against the xenogeneic cytokine. Future safety studies of IL‐10 or related therapeutics may require syngeneic large animal models.
Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts
Rohl, Stephen D., Miller, James L. , Knauf, Jeffrey A. , Ryder, Mabel , Milosevic, Dragana , Netzel, Brian C., Grebe, Stefan K., Smallridge, Robert C., Copland, John A. , Marlow, Laura A. , Knauf, Jeffrey A , Fagin, James A. , Reddi, Honey V. , Ryder, Mabel

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 25, 2018 | Volume: 103 | Issue: 9 | Pages: 3169-3182

10.1210/jc.2017-01845 | PMID 29846633 Get It